Based on an 'in-country caretaker' model, Quintiles aims to help Japanese pharma companies achieve their business goals in Europe with minimal bricks and mortar investment. The first of its kind in Europe, the Centre provides Japanese pharma companies with the services they need to successfully enter the European market. The new lab aims to create novel compounds for the treatment of allergies and diseases of the immune system.Īnd on the east coast Quintiles Transnational Corp opened its Japan Pharma Centre in Edinburgh. Staying in Glasgow, the West of Scotland Science Park is home to the Kyorin Scotland Research Laboratory, part of a £5.2m research and development deal between the Japanese Kyorin Pharmaceutical Company and Scottish Biomedical, the university-owned medical research company which specialises in finding commercial outlets for scientific research. Its work will involve close collaboration with pharmaceutical and medical companies to develop novel drugs, new technology and diagnostic equipment. The Centre is the first in the world to marry the expertise of biology, pharmacology and physics, using laser-based imaging technology. We believe Edinburgh could be one of the UK's best centres for manufacturing.”Īnother first for Scotland this year was the opening of a new £3m research Centre for Biophotonics at the University of Strathclyde in Glasgow, which aims to position Scotland at the forefront of biomedical science. Liam Fennell, biotechnology team leader, says: “Manufacturing is a major issue for the sector and there is a global shortage of manufacturing facilities. Jointly funded by Midlothian Council and Scottish Enterprise Edinburgh and Lothian, the site is expected to create up to 900 jobs. Outside Edinburgh, adjacent to the Pentland Science Park, the construction of Scotland's first bio-manufacturing park begins this summer.
Scotland is investing in significant infrastructure to support biotech's future development. Both firms carry out contract research for large drug groups.ĬlinTrials, based in North Carolina, primarily serves US drug firms seeking US Food and Drug Administration approvals, while Inveresk has traditionally focused on obtaining regulatory clearances in Europe. The company will add more than £72m in annual revenues, and staff numbers will rise from 800 to 2300.
In February Scottish contract Research Company, Inveresk Research, announced plans for a £78m take-over of its US rival, ClinTrials, which will see it almost triple in size. And Dundee-based Axis-Shield, Scotland's largest biotech company, has signed its first marketing agreement on a new test for Alzheimer's with California-based ICN Biomedicals.
#POINTER OPTIONS TRAILS SKIN#
Other Scottish-US collaborations include the Roslin Institute teaming up with Viragen to develop an antibody to skin cancer within a chicken egg that will allow the mass product of protein drugs for patient treatments.
In particular, the nation's relationship with the United States has generated a number of exciting business opportunities including an alliance with the US State of Maryland which has already generated deals for Scottish companies worth over £1.5m. The biotech community has delivered several landmark achievements following the launch in November 1999 of a four-year strategy to double the size of the Scottish cluster.
0 kommentar(er)
